home / stock / mdgef / mdgef short
Short Information | Medigene Ag Ord (OTCMKTS:MDGEF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 19,437 |
Total Actual Volume | 20,937 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 19 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 972 |
Average Short Percentage | 89.17% |
Is there a MDGEF Short Squeeze or Breakout about to happen?
See the MDGEF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
03-28-2024 | $2.43 | $2.43 | $2.43 | $2.43 | 500 | 500 | 100% |
03-25-2024 | $2.84 | $2.76 | $2.84 | $2.76 | 200 | 100 | 50% |
03-22-2024 | $2.72 | $2.53 | $2.72 | $2.53 | 200 | 100 | 50% |
03-21-2024 | $2.11 | $2.27 | $2.27 | $2.11 | 200 | 200 | 100% |
03-15-2024 | $1.93 | $1.93 | $1.93 | $1.93 | 2,000 | 2,000 | 100% |
12-27-2023 | $1.55 | $1.55 | $1.55 | $1.55 | 100 | 100 | 100% |
06-20-2023 | $2.11 | $2.11 | $2.11 | $2.11 | 500 | 500 | 100% |
05-10-2023 | $0 | $2.11 | $0 | $0 | 47 | 47 | 100% |
04-24-2023 | $2.11 | $2.11 | $2.11 | $2.11 | 100 | 100 | 100% |
04-04-2023 | $2.1 | $2.1 | $2.1 | $2.1 | 1,000 | 1,000 | 100% |
03-29-2023 | $2.1 | $2.1 | $2.1 | $2.1 | 2,500 | 1,500 | 60% |
01-31-2023 | $2.3 | $2.3 | $2.3 | $2.3 | 5,000 | 5,000 | 100% |
12-19-2022 | $2.15 | $2.15 | $2.15 | $2.15 | 200 | 200 | 100% |
11-28-2022 | $2.35 | $2.35 | $2.35 | $2.35 | 1,000 | 900 | 90% |
09-30-2022 | $2.05 | $2.05 | $2.05 | $2.05 | 210 | 210 | 100% |
09-21-2022 | $2.1 | $2.1 | $2.1 | $2.1 | 1,000 | 1,000 | 100% |
07-06-2022 | $2.4 | $2.4 | $2.4 | $2.4 | 2,700 | 2,700 | 100% |
04-19-2022 | $3.1 | $3.1 | $3.1 | $3.1 | 180 | 180 | 100% |
02-28-2022 | $3.92 | $3.92 | $3.92 | $3.92 | 3,000 | 3,000 | 100% |
02-24-2022 | $3.87 | $3.96 | $3.96 | $3.87 | 300 | 100 | 33.33% |
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...